Lisata Therapeutics, Inc. (LSTA)
- Previous Close
2.9300 - Open
2.9000 - Bid --
- Ask --
- Day's Range
2.8922 - 3.0885 - 52 Week Range
1.9600 - 3.8300 - Volume
13,645 - Avg. Volume
12,591 - Market Cap (intraday)
24.21M - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5600 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
www.lisata.comRecent News: LSTA
View More
Performance Overview: LSTA
Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LSTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LSTA
View MoreValuation Measures
Market Cap
24.21M
Enterprise Value
-13.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.63
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.72%
Return on Equity (ttm)
-44.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.07M
Diluted EPS (ttm)
-2.5600
Balance Sheet and Cash Flow
Total Cash (mrq)
38.26M
Total Debt/Equity (mrq)
0.59%
Levered Free Cash Flow (ttm)
-13.25M
Research Analysis: LSTA
View MoreCompany Insights: LSTA
LSTA does not have Company Insights